Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)’s stock price hit a new 52-week high on Thursday . The company traded as high as $3.98 and last traded at $3.94, with a volume of 2894244 shares traded. The stock had previously closed at $3.60.

A number of equities analysts have weighed in on the company. Zacks Investment Research raised Investar from a “hold” rating to a “buy” rating and set a $27.00 target price for the company in a research report on Tuesday, June 4th. BidaskClub raised Xilinx from a “hold” rating to a “buy” rating in a research report on Wednesday. ValuEngine raised Worldline from a “hold” rating to a “buy” rating in a research report on Tuesday. Finally, Barclays set a $24.00 target price on Orion Engineered Carbons and gave the stock a “hold” rating in a research report on Friday, May 3rd. Two research analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the stock. Achillion Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $2.75.

The firm has a market capitalization of $546.58 million, a PE ratio of -9.12 and a beta of 1.88. The company’s 50-day moving average price is $2.79.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.14) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.14). On average, equities analysts predict that Achillion Pharmaceuticals, Inc. will post -0.59 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. raised its position in Achillion Pharmaceuticals by 1.5% in the fourth quarter. BlackRock Inc. now owns 12,101,177 shares of the biopharmaceutical company’s stock worth $19,241,000 after purchasing an additional 175,818 shares in the last quarter. Raymond James & Associates increased its holdings in shares of Achillion Pharmaceuticals by 11.6% during the fourth quarter. Raymond James & Associates now owns 71,450 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 7,400 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Achillion Pharmaceuticals by 3.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 7,442,477 shares of the biopharmaceutical company’s stock worth $11,833,000 after buying an additional 259,762 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Achillion Pharmaceuticals by 6.3% during the fourth quarter. Geode Capital Management LLC now owns 1,547,004 shares of the biopharmaceutical company’s stock worth $2,459,000 after buying an additional 91,346 shares in the last quarter. Finally, Two Sigma Investments LP increased its holdings in shares of Achillion Pharmaceuticals by 2,305.8% during the fourth quarter. Two Sigma Investments LP now owns 1,171,696 shares of the biopharmaceutical company’s stock worth $1,863,000 after buying an additional 1,122,993 shares in the last quarter. 79.30% of the stock is owned by hedge funds and other institutional investors.

Achillion Pharmaceuticals Company Profile (NASDAQ:ACHN)

Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.

Featured Story: Leveraged Buyout (LBO)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.